Abstract
Reduced humoral immune response after mRNA vaccination correlates with breakthrough SARS-CoV-2 infection in ocrelizumab-treated multiple sclerosis patients (P12-3.005)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
